1/246
Looks like no tags are added yet.
Epidemiology Triangle
Host, Agent, Environment
Host
the organism affected by a disease, which can be human, animal, or plant. It interacts with agents and environments affecting disease occurrence
Example: human, animal, etc.
Agent
any factor that causes disease, including viruses, bacteria, and toxins. It influences the host's health status in the epidemiological process.
Examples: SARS CoV, HIV, parasite, Cholera
Environment
all external or extrinsiv factors: physical, biological, social, economic conditions. Provides opportunity for exposure to disease transmission
Example:
Physical: climate, weather, air, soil, water quallity
Biological: living organisms and vectors → harbor, breed, transmit disease agents (bacteria, rodents)
Socioeconomic/Cultural: human infrastructure, societal influence, population density, sanitation, poverty, cultural habits, healthcare access
Epidemiology
Epi (upon)
Demos (people)
Ology (study)
Study upon people
Infectious Disease Epidemiology
Study of the incidence and Mspread of infectious disease in population overtime
Microbes
organisms seen only with a micrscope
Example: bacteria, algae, protozoa..sometimes virus (debated = nonliving)
Risk factor
Something that increases a person’s chance of getting a disease
Action: smoking
Host: # of people with influenza, # of people vaccinated
South Korea MERS Outbreak
Saudia Arabia MERS outbreak
Korean business man smoked inside airport room
Infected with MERS ——Korea Emergency Department
“Hospital shopping culture” - many hospitals for quality results (free healthcare)
Superspreader (infected 82 ppl)
Incidence
Number of NEW persons who fell ill in the time period DIVIDED by TOTAL population
Time: if not specified, assumed to be 1 year
Use: causation of disease OUTBREAK
Numerator: Number of new cases of disease
Prevalence
ALL cases (old and new) in the total population at a SPECIFIC TIME
Use: Measure disease burden (HIV/AIDS, Hep B)…not used as much in infectious disease
Numerator: Old and new cases
Incidence + Prevalence Shared Denominator
Must take into account of “total population size”
Example: Sweden population = 2x Denmark (# of cases = double Denmark)
Case-Fatality Rate (CFR)
Proportion of people who die out of those who get a specific disease
#of deaths from a disease/ # of cases of disease
Use: seriousness of disease
Mortality Rate
Measure of the frequency of occurrence of death in TOTAL POPULATION caused by a specific disease (specific time interval)
Use: Tracks overall population health (improving/declining)
Attack Rate
Probability of people EXPOSED to an infectious agent becoming ILL
Use: infectivity
Equation: # of people ill / # of people at risk of illness
Basic Reproductive Rate (R0) Defintion
Average # of persons directly infected by infectious cases (during the infectious period) entering a TOTALLY SUSCEPTIBLE POPULATION (no immunity)
Use: measures probability of spread when NEW DISEASE enters population
Epidemic
R0>1 - every infected person on average infects ONE or MORE people
Endemic
R0 = 1 - same number of people infected overtime
Disease dies out
R0<1 - less than one person is infected each time…disease dies out
Basic Reproductive Rate (R0) Equation
R0 = beta * k * D
beta = risk of transmission per person (attack rate)
Face masks, condoms, hand washing
k = average number of contacts (per time)
isolation, closing school
D - duraction of infectivity of infected person
specific for disease
decrease: early diagnosis + treatment
Herd Immunity
A significant proportion of the population (herd) has been VACCINATED, providing protection for susceptible individuals
Herd Immunity Threshold (HIT)
Minimum proportion (P) of population need to be immunized
Goal: R = 1 ...endemic for stable infectious disease
R = (1-P)R0
P = proportion of immune population…R = 1
P = 1 - (1/R0)
R0 = 5… then vaccine coverage needs to be more than 80%
Incubation Period
Time from infection to SYMPTOM onset
Latent Period
Time between infected to being INFECTIOUS
Generation Time
Time between the generation of INFECTION
cannot be observed
Serial Interval
Time between SYMPTOM onset between generation (observable)
Infectious before symptoms onset
Latent period shorter……than incubation period
Greater risk of spread
Symtomatic before infectious
Incubation period shorter…..than latent period
Easier to curb infection
Determing how fast an epidemic grows
Generation time + R0
HIV stands for
Human Immunodeficiency Virus
HIV Family
Retrovirus - single stranded RNA
Subfamily: Lentivirus (Lenti - slow…dormant after getting into host cell)
HIV Outer Membrane
Phospholipid Bilayer ( two layers of fat molecules)
Unique structure - takes part of host membrane
GP 120
Spike used to enter host cell
Capsid
Peptide layer surrounding 2 identical single-stranded RNA
Reverse Transcriptase
Use RNA to convert into DNA…used to pass through host membrane
Integrase
insert viral DNA into host cell DNA (CD4)
Protease
Use to cleave long peptide chains for formation of new HIV
CD4 Cell
Helper T Cell, CD4+ lymphocyte
CD4 - general of army…signals for immune response to anCD4 invader
CD4 Count
Normal: 500 - 1500 cells/mm³
Bacteria Pnemonia: below 500 cells/mm³
HIV damage (TB susceptible) - below 300 cells/mm³
Severe HIV damage (parasitic infection susceptible) - equal 200 cells/mm³
AIDS: below 200 cells/mm³
Traditional: start ART 500-250 cells/mm³
Novel: start immediately
HIV Life Cycle
AFRITAB (Africa Tab)
Attachment
GP120 docking protein (spike on HIV) interacts with CD4 receptor
Coreceptor interactions - CCR5 and CXCR4 interact specfically
Fusion
HIV enters CD4 cell, dumping its contents
Contents: reverse transcriptase, integrase, protease
Reverse Transcriptase
Makes copy from RNA to DNA (double-stranded)
Reverse Transcriptase
Integration
Viral DNA integrates with host DNA at the nucleus of CD4 cell
Integrase
Transcription
Information making new HIV is released from the nucleus…become LONG CHAINS of protein
Assembly
Packages of information getting ready to leave CD4 cell at plasma membrane
Protease - cleave long polypeptides into packages
Budding
Final step of replication, packages pushes itself out of host cell
takes host plasma membrane
Mutations in HIV
HIV Reverse Transcriptase - error-prone
Creates drug resistance and mutations
Killing CD4 Cell
HIV replicate in host CD4 cell → leads to CD4 cell death
6 Classes of HIV Medication
NRTIs (Nucleoside Reverse Transcriptase Inhibitor)
NNRTIs (Non-nucleoside Reverse Transcriptase Inhibitor)
PIs (Protease Inhibitors)
IIs (Integrase Inhibitors)
Entry Inhibitors (Fusion)
Boosters - Pharmacokinetic Enhances
NRTIs
Nucleoside Reverse Transcriptase Inhibitor
Prevent HIV RNA making HIV DNA
NNRTIs
Non-nucleoside Reverse Transcriptase Inhibitors
Blocking specific PROTEIN used during Reverse Transcription to prevent transcription of HIV DNA
PIs
Protease Inhibitors
Prevent protease enzyme from cutting long chain into packages for new HIV
IIs
Integrase Inhibitors
Attacks integrase protein…prevent attachment of HIV DNA to CD4 DNA
Newer class of medication (2007)…pateints with RESISTANCE
Entry Inhibitors (Fusion)
block HIV attaching to CCR5 receptor (co receptor)…cannot dump its contents
Boosters
Pharmacokinetic Enhances
Does not interfere with HIV Life Cycle
Boosts the strength of other HIV medications
HIV Vaccine
Not available to HIV/AIDS
- error prone -
individual may have many different mutations of HIV
HIV-1
99% of current pandemic
4 distant groups
M, N, O, P
O, N - geogrpahically limited to Africa
M - 9 subtypes (A to K) + CRF
Subtypes - geographically limited
Circulating Recombinant Form (CRF)
Recombinant subtypes - Southeast Asia (common A and E)
I and E
55 CRFs
HIV-2
Less virulent - almost asymptomatic
HIV/AIDS Timeline
1981 - diagnosed in a homosexual man in California
unusual symptoms - cough, fungal infection, lung pain, pale
Diagnosed with PCP (Pneumonia)…only found in elders, infants, cancer-pt
1982 - labeled “gay cancer” “gay plague”
New York, SF, LA
1985 - Pandemic
Africa (Black-faced chimpanzee, SIV mutation) → Haiti (West African ties) → Dominican Republic (popular vacation spot) → US (DR common for men having men relation) → global
Berlin Patient
Timothee Brand - “cured” of HIV
Bone marrow transplant for stem cells - natural resistant to HIV/AIDS
Missisipi Baby
2nd successful case - relapsed 4 years after
aggressive cocktail therapy (29 hours hold)
Public health problem
Surveillance, condom distribution, needle exchange
Human rights problem
Stigmatization - PLHIV - refused by doctors, fired from jobs, believed to still be infectious on ART
Security Problem
Post-Cold War - security moved away from war...onto nonmilitary threats
Securized Process
Speech Acts
Audience Acceptance
Emergency Measures
MAIN GOAL: desecuritisation
Speech Acts
Top political leader frame issue as security threat
Audience acceptance
Target audience (citizens, lawmakers) accept
Begin to plan reallocating funding for percieved threat
Emergency measures
Compulsory policies, formation of special governmental bodies
Example:
MAP - World Bank’s Multi-Country AIDS Programme
Global Fund - fight AIDS, TB, Malaria
PEPFAR - President’s Emergency Plan for AIDS Relief
AIDS Exceptionalism
TWO WAVES
1980 - 1st initiated by gay community stigmatized (needed exceptional movement)
1996 - ART development, low cost…fall of exceptionalism
2000 - Jan 2006 Al Gore speech about security threat (rise again)
2008 - Global Financial Crisis…backlash and withdraw from funding
Horizontal vs Vertical Health Program
Vertical Program - disease-specific
Move HIV towards chronic primary healthcare (reduce stigma)
Horizontal Program - tackle overall health problems, general health services
Project 2030
Moved from 90-90-90 (2020) to 95-95-95 by 2030
2020 not met: 90-81-73
95% of people infected with HIV know they are infected with HIV
95% of people known with HIV receive ART
95% of people who recieve ART achieve viral supression
Influenza Virus Overview
Family: Orthomyxoviridae
Type: A, B, C, D
B, C, D - non-human threat (only in animals)
C - causes mild illness
D - cattle
B - less severe (no pandemics)
Influenza A
Causes human pandemics
2 subtypes:
HA - hemagglutinin - H1 to H18
NA - neuraminidase - N1 to N11
Types of HA and NA endemic to HUMANS
HA - H1, H3
NA - N1, N2
—causes seasonal outbreaks—-
Bird + Swine
Sporadic outbreaks…needs mutation to infect humans for pandemic
Example: H5N1, H9N2, H7N7
Influenza B
2 lineages
B/Yamagata
B/Victoria
Antigenetic Drift
small accumlations of mutations
leads to small antigenic changes OVERTIME
A and B subtypes
Seasonal influenza
Remains HA NA specific
Antigenetic Shift
Large scale change
non-human influenza infects human host
REASSORTMENT of animal and human subtype (double/triple reassortment)
Influenza A ONLY
Pandemic - population has little to no immunity against
Example: Asian Influenza (H2N2), Spanish Flu (H1N1), Hong Kong (H3N2)
Avian Flu (H5N1)
Hisotry of Influenza
H3N8 - Russian Flu (1889)
H1N1 - Spanish Flu (1918)
H2N2 - Asian Flu….replaced Spanish Flu (1957)
H3N2 - Hong Kong Flu…replaced Asian Flu (1968)
H1N1 - resurfaced (1977) recirculates with H3N2
H5N1 - Avian Flu (1997)
H1N1 (Swine Flu) - resurfaced (2009)
H7N9 - China outbreak (2013) confined…not pandemic)
Influenza Nomenclature
Type/(sometimes Animal/Person Reside)Location/Strain#/Year (Virus Subtype)
Example:
A/Hong Kong/156/97 (H5N1)
A/Swine/###/2009 (H1N1)
Influenza Outer Envelope + Genetic Material
Sphereical envelope virus - lipid membrane (from host cell)
8 RNA genetic material
M2 + M1
(M2) Ion channel - viral UNCOATING for early replication
(M1) Matrix protein - creates endosome
Glycoprotein spikes (on lipid membrane)
HA - hemaglutinin - receptor binding site for sialic acid
Alpha 2.3 linked SA - common in DUCK gut epithelium
H5N1 - higher case fatality (pneumonia)
Alpha 2.6 linked SA - common in HUMAN upper respiratory (trachael)
NA - Nema - final stage of infection after budding
removed SA from both receptors
Prevents virus form binding to DYING host cell
“release”
Antiviral Drugs for Influenza
Amantadine - M2 interference
Rimantadine - M2 interference
Does not work for Type B
Typa A : 70 - 90% effective
Tamiflu - inhibit NA (2009…newer drug)
H1N1 Pandemic - 2009
Swine Flu
Subtype A
Antigenetic Shift - no immunity to NOVEL virus
Mixing Vessel: Pigs
human + avian + swine
Misunderstanding: pig = reason for infectious spread (lead to slaughter)
H1N1 PHEIC
April 2009 - declared
(38 days after 1st oubreak in Mexico → California)
ControversialPubli, Ebola: 138 days for PHEIC
Gain-Of-Function Research (GOF)
“Superbug” worries
Recombinant exchange of gene segments
GOF research - acquisition of new function
Experiment with recombinants for better preparation
Risk: escape from lab (COVID-19 early suspicions)
Coronavirus Family + Types
Family - orthocoronavirinae
Subfamily - coronavirdae
4 types:
Alpha and beta coronavirus - infect HUMANS
2 alpha + 2 beta - known corona virus infections
Gamma and delta - infect only ANIMALS
SARS-coV 1
2002 - 2003
Beta coronavirus - Severe Acute Respiratory Syndrome
Index case: Guangdong (Southern China)
Intermediate Host - cevic cat + racoon dog
culture: eaten for medical reasons (normally resides in rural areas)
Infectivity - similar to COVID-19 (not as rapid rate)
Case Fatality: 7%
MERS-coV
2012
Beta coronavirus - Middle Eastern Respiratory Syndrome
Saudi Arabia - novel beta coronavirus
Intermediate host: camels
Case Fatality: 34.4%
Infectivity: low transmission rate
SARS-coV 2
2019
beta coronavirus subtype
Index Case: Wuhan China (unsure exact source)
Infectivity: rapid spread
Case Fatality: 2%
Spike Proein (S proteins)
targets ACE2 on host cell and DPP-4
ACE 2
Angiotensin-converting enzyme II
ACE2 - highly expressed in the respiratory tract, epithelial in the bronchi, alveoli, and trachea
DPP-4 receptor
MERS-coV spike - binds to dipeptidyl peptidase 4
DDP-4 lower respiratory tract (severe pneumonia)
Remesivir
First FDA approved drug for COVID -19
RNA polymerase inhibitor
Previously used for Hep C and Ebola
Emergency grant (authorization)
FDA allows certain life saving drug streatment ——-no alternative approved medication
benefits outweigh risks
Baricitinib
FDA emergency grant for rheumatoid arthritis for HOSPITALIZED patients
Molnupiravir
developed by Merck
RNA Polymerase (mild to moderate risk)